Blood/Immune System Cells TRIZ Cases

Adding a 4-1BB agonist to IL-2 tumor fragment culture speeds TIL expansion and enriches tumor-reactive CD8+ cells for ACT.

Umbilical cord blood-derived Treg cells improve lung targeting, stability, and repeat dosing for pulmonary disorder treatment.

A sub-300-amino-acid CAR design uses single co-stimulation and optimized CD3ζ signaling to improve persistence, tumor killing, and toxicity control.

Dot-patterned cell scaffolds control cluster size and spacing to stabilize hematopoietic progenitor and leukocyte differentiation from pluripotent stem cells.

Early apheresis collection with predictive biomarkers preserves T cell quality for CAR T manufacturing and improves patient stratification.

Feeder-free iPSC differentiation produces mature NK cells with strong cytotoxicity, reducing process complexity and contamination risk.

Frozen splenocytes activated by test and reference vaccine dilutions enable faster, more direct potency and immunogenicity measurement.

A two-stage TIL restimulation process boosts memory T cell subsets and metabolic health to improve persistence after transfer.

HLA-homozygous cells reduce allogeneic immune recognition by using specific homozygous allele combinations to improve transplant compatibility.

Closed monocyte enrichment and staged cytokine treatment enable scalable cGMP production of mature dendritic cells with lower contamination risk.

Memory lymphocytes with CD3/CD4/CD8 and related markers target residual liver cancer cells to reduce recurrence, metastasis, and relapse.

Early apheresis collection and biomarker-based stratification preserve T cell quality and improve CAR T therapy manufacturing and response.

Defined growth-factor media replace serum and feeder cells to produce functional NK cells for in vivo administration with high yield and purity.

A combined antibody, cytokine, and superoxide dismutase culture medium drives peripheral blood regulatory T cell differentiation for autoimmune therapy.

CD4+ T-cell-derived extracellular vesicles activate CD8+ T cells, increasing proliferation and cytotoxicity for cancer treatment.

A staged IL-2, IL-7, and IL-12 culture shortens IL-12 exposure, reducing CIK cell necrosis while maintaining activity for tumor treatment.

Separate soluble monospecific tetrameric complexes activate and expand T or NK cells without immobilized antibodies or added growth factors.

Because most MSS CRC patients resist checkpoint inhibitors, EV-loaded dendritic cells lacking miR-424 increase CD8+ T-cell infiltration.

During ex vivo culture, HDAC inhibitors help prevent natural killer cell death, improving viable yield for cell therapy.

CD8+ and regulatory T-cell depletion provides donor CD4+ help to host CD8+ cells while limiting engraftment and graft-versus-host disease risk.

A buffered chitosan suspension preserves simulated blood-cell characteristics for digital imaging analyzers and leukocyte differential quality control.

This case combines VCAM, ICAM, DLL4, and SCF/TPO/Flt3L/IL-7 to increase initial γδ T-cell production without costly expansion.

This case removes CD4−CD8− cells before maturing CD4+CD8+ cells, supporting a high-purity, antigen-specific CD8+ T-cell culture.

An HSA, MgCl2, and Dornase alfa buffer supports thawing, while IL-2, rapamycin, and TGF-β drive functional T-reg expansion.

This case replaces immobilized antibodies, accessory cells, and growth factors with soluble monospecific complexes for T/NK expansion.

This case uses pICF to bring T cells close to cancer cells, transfer surface markers, and enrich selectively active trogocytotic T cells.

Merging multiple blood cell types increases iPS establishment efficiency while maintaining donor DNA match.

Flow cytometry detection of CD134 and CD137 markers on stimulated lymphocytes replaces complex proliferation assays to reduce time and equipment costs.

A rotatable bed reactor uses a porous matrix to process megakaryocytes into platelets.

Forming blood-born hematospheres in ultra-low attach dishes overcomes limited supply and harvesting difficulties by enabling efficient in vitro proliferation.

Shrinking and fixing nucleated red blood cells creates distinct optical properties for automated hematology analyzers.

MEK1/2 inhibitors convert CD4+ T cells into stem cell-like memory T cells, addressing limited clinical responses in PD-1 immunotherapies.

Calibrated ultrasound creates microscopic turbulence near cell walls, resolving stagnant nutrient transfer bottlenecks to boost protein expression rates.

Staged production with gas permeable surfaces increases cell growth rates while reducing lengthy production times.

A method isolates autologous cancer antigen-specific CD8+ T cells using an anti-4-1BB antibody-coated plate to selectively capture activated immune cells.

Chemotactic gradients separate hematopoietic progenitors by migration to quantify function, resolving imprecise manual counting bottlenecks.

Aptamer carriers localize within processing compartments to activate specific T cells without intrinsic immunostimulatory side effects.

Closed automated bioreactor expands NK cells via controlled agitation, eliminating contamination risks inherent in manual flask methods.

Exosomes from transfected dendritic cells deliver survivin antigens to stimulate targeted immune responses.

Sedimentation and immunomagnetic beads enrich hematopoietic stem, NK, and T cells from umbilical cord blood, reducing graft-versus-host disease risk.

Antibody-conjugated superparamagnetic iron oxide nanoparticles enable targeted internalization within specific cell populations for magnetic resonance imaging.

Chimeric antigen receptors with CD20 safety switches enable controlled cell removal.

An artificial immune system using cultured human cells assesses vaccine efficacy in vitro.

Expanding peripheral blood mononuclear cells with FLT-3L, TPO, SCF, IL3, IL6, and SR1 before differentiating them yields high-purity cDC1s for clinical use.

Using feeder cells and interleukins to expand gamma delta T cells, reducing patient burden from large blood draws.

Aptamer sequences bind monocytes and macrophages to resolve low isolation specificity in biological samples.

Mature dendritic cells mediate antigen presentation to bypass inefficient cross-presentation, simplifying vaccine standardization.

Removing feeder cells from cytokine-based culture resolves regulatory barriers while enabling large-scale NK cell production.

Two CRISPR nickases generate single-strand breaks in regulatory elements, avoiding double-strand cuts that cause malignant transformations.

Standardized allogeneic tumor cell lysate loads dendritic cells to overcome autologous material scarcity and boost mesothelioma treatment efficacy.

TGF-beta vaccine polypeptides neutralize tumor immune suppression to enhance anti-cancer efficacy alongside checkpoint blockers.